New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy
More than 90% of patients had a complete response to novel treatment combination
After two years, 97% of patients remained cancer free
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies – brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine...
Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy
Linavonkibart, also known as SRK-181, is an experimental therapy from Scholar Rock that aims to prevent or overcome resistance to immune checkpoint...
Mutation predicts chemotherapy resistance and better responses to immunotherapy in advanced bladder cancer
Researchers studied the KDM6A gene, which is altered in about 26% of advanced bladder cancers
Tumors with KDM6A mutations did not respond well...
Higher bacteria levels inside tumors can promote immunotherapy resistance in head and neck cancer
Researchers found that the amount, and not the type, of bacteria inside tumors can predict response to treatment in lab models of head and neck cancer
Higher amounts of bacteria create an immunosuppressive tumor microenvironment
This understanding could identify patients more likely to benefit from immunotherapy and guide clinicians to ...
Dual-antigen targeting of large B-cell lymphoma shows promise in reducing relapse
Large B-cell lymphoma (LBCL) is an aggressive blood cancer with few treatment options
CAR T cell therapy targeting...
Immunotherapy before and after surgery improved outcomes in lung cancer patients with lymph node metastases
Perioperative nivolumab plus neoadjuvant chemotherapy improved outcomes for patients regardless of...
Immunotherapy combination does not improve outcomes for patients with advanced anal cancer
Phase II ETCTN trial found ipilimumab plus nivolumab did not improve outcomes over nivolumab alone in...
Researchers identify novel therapeutic target to improve recovery after nerve injury
Peripheral nerve injury reduces the ability of macrophages to clear dead or dying cells – a process known as efferocytosis – leading to chronic...
High levels of protein drive tumor immune suppression in head and neck cancer
BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment
Glutamine...
Targeted therapy plus immunotherapy improved outcomes in advanced metastatic colorectal cancer
Phase III COMMIT trial evaluated better first-line options for patients with dMMR/MSI-H metastatic colorectal cancer
The study...
Circadian rhythms may affect risk of bacterial infection
Researchers identified an inflammation biomarker in laboratory model that predicts which individuals are at an increased risk of bacterial infection...